Importantly, gene expression analysis in breast cancer patients demonstrated shorter survival when fascinhigh was coexpressed with high FAK or high β-catenin downstream targets, demonstrating a clinical relevance of our in vitro data. This evidence concerns the gene PTK2 and breast cancer.